Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma.

Citation data:

Cancer management and research, ISSN: 1179-1322, Vol: 5, Issue: 1, Page: 197-203

Publication Year:
2013
Usage 91
Downloads 79
Abstract Views 12
Captures 15
Readers 15
Citations 15
Citation Indexes 15
Repository URL:
https://digitalcommons.unmc.edu/com_bio_articles/54
PMID:
23940421
DOI:
10.2147/cmar.s45976
PMCID:
PMC3736971
Author(s):
Macha, Muzafar A.; Batra, Surinder K.; Ganti, Apar Kishor
Publisher(s):
Dove Medical Press Ltd.
Tags:
Medicine; basal cell carcinoma; vismodegib; hedgehog pathway; Medical Biochemistry; Medical Molecular Biology
article description
Basal cell carcinoma (BCC) is the most common human malignancy. Recent advances in our understanding of the critical biologic pathways implicated in the development and progression of BCC have led to the development of the first molecular targeted therapy for this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials with vismodegib, an inhibitor of this pathway, have shown significant responses. This review will discuss the importance of the hedgehog pathway in the pathogenesis of BCC and describe in detail the pharmacology of vismodegib in relation to its activity in advanced BCC.